Clinical Trial Update: MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study MT-601 in locally advanced unresectable or metastatic pancreatic cancer; study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• MT-601

Snippet

Sponsor: Marker Therapeutics, Inc. | Conditions: Pancreas Cancer | Phase 1 | Status: NOT_YET_RECRUITING